Editorial Material
Oncology
Sun Min Lim, Chang Gon Kim, Byoung Chul Cho
Summary: Treatment resistance to targeted agents is a significant challenge in cancer therapy and is also observed in EGFR-mutant NSCLC. Current efforts focus on delaying or overcoming acquired resistance, and targeting compensatory feedback loops along with oncogenic signaling pathways holds promise for improved outcomes.
Article
Oncology
Zhenhua Li, Yaqiang Pan, Qinghua Liu, Jian Wang, Chang Liu, Laihao Qu, Dingbiao Li
Summary: The expression of GPER1 is associated with ER and EGFR mutations in lung adenocarcinoma. GPER1 regulates ER expression and MAPK signaling, and co-inhibition of GPER1 and ER can decrease phosphorylation of ERK1/2 and Akt in cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biology
Xiaolong Tang, Lizhi Cheng, Guo Li, Yong-Ming Yan, Fengting Su, Dan-Ling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li, Yong-Xian Cheng, Baohua Liu
Summary: The small molecule compound D6 demonstrates promising efficacy in treating EGFR-TKI resistant NSCLC by targeting the protein-protein interaction between HSP90 and T790M-EGFR, offering a potential alternative strategy to overcome drug resistance.
COMMUNICATIONS BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Haojie Jin, Yaoping Shi, Yuanyuan Lv, Shengxian Yuan, Christel F. A. Ramirez, Cor Lieftink, Liqin Wang, Siying Wang, Cun Wang, Matheus Henrique Dias, Fleur Jochems, Yuan Yang, Astrid Bosma, E. Marielle Hijmans, Marnix H. P. de Groot, Serena Vegna, Dan Cui, Yangyang Zhou, Jing Ling, Hui Wang, Yuchen Guo, Xingling Zheng, Nikita Isima, Haiqiu Wu, Chong Sun, Roderick L. Beijersbergen, Leila Akkari, Weiping Zhou, Bo Zhai, Wenxin Qin, Rene Bernards
Summary: Inhibition of EGFR is synthetically lethal with lenvatinib in liver cancer, and the combination of lenvatinib with the EGFR inhibitor gefitinib shows potent anti-proliferative effects both in vitro and in vivo. This combination therapy could be a promising strategy for HCC patients with high levels of EGFR, providing meaningful clinical responses.
Article
Oncology
Masaki Kanazu, Masahide Mori, Madoka Kimura, Kazumi Nishino, Takayuki Shiroyama, Izumi Nagatomo, Shoichi Ihara, Kiyoshi Komuta, Hidekazu Suzuki, Tomonori Hirashima, Toru Kumagai, Fumio Imamura
Summary: The study found that both first- and second-generation EGFR-TKIs have favorable responses in NSCLC patients with uncommon EGFR mutations. Patients with G719X mutation had a more favorable progression-free survival compared to those with L861Q mutation and compound mutations. EGFR-TKIs not only present favorable responses but also contribute to long-term disease control in NSCLC patients with uncommon EGFR mutations, surpassing the effects of cytotoxic chemotherapy and immune checkpoint inhibitors.
Article
Cell Biology
Ke-Ren Zhang, Yu-Fei Zhang, Hui-Min Lei, Ya-Bin Tang, Chun-Shuang Ma, Qian-Ming Lv, Shi-Yi Wang, Li-Ming Lu, Ying Shen, Hong-Zhuan Chen, Liang Zhu
Summary: The study uncovered a metabolic mechanism driving resistance to EGFR TKIs by promoting cystine metabolism, and suggested AKR1B1 as a potential therapeutic target to overcome resistance to EGFR TKIs.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Biophysics
Parimala Devi Ganthala, Sateesh Alavala, Naveen Chella, Sai Balaji Andugulapati, Nagendra Babu Bathini, Ramakrishna Sistla
Summary: Erlotinib-based EGFR targeted therapy has shown significant clinical improvement against non-small cell lung cancer. However, the development of drug resistance limits its effectiveness. In this study, the combination of Erlotinib and Quercetin was found to be more synergistic against certain lung cancer cells compared to other natural products. By preparing drug-loaded nanoparticles, the encapsulation efficiency and release performance of the drugs were improved. The nanoparticles could reduce the expression of drug-resistant proteins, increase drug uptake, and induce apoptosis in drug-resistant cells. In vivo experiments also showed increased uptake of nanoparticles in lung tissue and decreased expression of cancer-related genes.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2022)
Article
Biochemistry & Molecular Biology
Tamara Reyes-Robles, Aleksandra K. Olow, Tyler J. Bechtel, Scott A. Lesley, Olugbeminiyi O. Fadeyi, Rob C. Oslund
Summary: Receptor tyrosine kinases play essential roles in cell signaling, with mutations or overexpression potentially leading to diseases such as cancer. Strategies targeting multiple RTKs, like EGFR and c-MET, have emerged to overcome therapeutic resistance.
ACS CHEMICAL BIOLOGY
(2022)
Article
Oncology
Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, Yukio Hosomi, Kana Watanabe, Satoshi Ikeda, Masahiro Seike, Yuka Fujita, Koichi Minato, Ryo Ko, Toshiyuki Harada, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue
Summary: In this study, gefitinib plus chemotherapy was compared with gefitinib monotherapy in patients with non-small-cell lung cancer. The results showed that gefitinib plus chemotherapy significantly improved progression-free survival and had good long-term tolerability.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
G. R. Hancock, K. S. Young, D. J. Hosfield, C. Joiner, E. A. Sullivan, Y. Yildiz, M. Laine, G. L. Greene, S. W. Fanning
Summary: This study identified chemically unconventional antagonists of estrogen receptor alpha (ERα) that have moderate effects on the transcriptional activities of breast cancer cells, exhibit anti-proliferative properties, and engage transcriptional pathways similar to selective estrogen receptor degraders.
Article
Multidisciplinary Sciences
Mari Tone, Kota Iwahori, Takayuki Shiroyama, Shinji Futami, Yujiro Naito, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hisashi Wada, Yoshito Takeda, Atsushi Kumanogoh
Summary: Minocycline administration in NSCLC patients treated with first-line EGFR-TKIs was found to correlate with longer PFS and OS, independent of skin rash. This retrospective analysis suggests that minocycline may have a positive impact on the treatment outcomes of EGFR-mutant NSCLC patients.
SCIENTIFIC REPORTS
(2023)
Article
Pharmacology & Pharmacy
Cong Xu, Ze-Bo Jiang, Le Shao, Zi-Ming Zhao, Xing-Xing Fan, Xinbing Sui, Li-Li Yu, Xuan-Run Wang, Ruo-Nan Zhang, Wen-Jun Wang, Ya-Jia Xie, Yi-Zhong Zhang, Xiao-Wen Nie, Chun Xie, Ju-Min Huang, Jing Wang, Jue Wang, Elaine Lai-Han Leung, Qi-Biao Wu
Summary: This study found that the combination of ll-elemene and erlotinib induced ferroptosis and enhanced the sensitivity to EGFR-TKIs in EGFR-TKI-resistant lung cancer patients.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Oncology
Carolin Selenz, Anik Compes, Marieke Nill, Sven Borchmann, Margarete Odenthal, Alexandra Florin, Johannes Braegelmann, Reinhard Buettner, Lydia Meder, Roland T. Ullrich
Summary: EGFR inhibition promotes immune cell infiltration in the tumour microenvironment and enhances response to immune checkpoint inhibitors in EGFR-driven lung cancer.
Article
Chemistry, Medicinal
Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Chris De Savi, Timothy J. Guzi, Brett D. Williams, Douglas Wilson, Kevin Wilson, Natasja Brooijmans, Joseph Kim, Aysegul Ozen, Emanuele Perola, John Hsieh, Victoria Brown, Kristina Fetalvero, Andrew Garner, Zhuo Zhang, Faith Stevison, Rich Woessner, Jatinder Singh, Yoav Timsit, Caitlin Kinkema, Clare Medendorp, Christopher Lee, Faris Albayya, Alena Zalutskaya, Stefanie Schalm, Thomas A. Dineen
Summary: While EGFR tyrosine kinase inhibitors have revolutionized the treatment of NSCLC, the development of resistance mutations remains a challenge. This study introduces a novel reversible inhibitor, BLU-945, that shows promising activity against different resistance mutations. Clinical trials are currently underway to evaluate its efficacy and safety.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Engineering, Biomedical
Duo Wang, Jun Zhou, Weimin Fang, Cuiqing Huang, Zerong Chen, Meng Fan, Ming-Rong Zhang, Zeyu Xiao, Kuan Hu, Liangping Luo
Summary: In this study, a multifunctional superparamagnetic nanotheranostic agent was developed to enhance the efficacy of Erlotinib in EGFR-wt NSCLC. The nanoparticles co-delivered Erlotinib and a VEGF inhibitor (Bev) to EGFR-wt tumors, inhibiting tumor growth and promoting vascular normalization. The tumor engagement of nanoparticles and vascular normalization could be tracked by MRI.
BIOACTIVE MATERIALS
(2022)
Article
Oncology
Xinyu Deng, Sophia Apple, Hong Zhao, Jeongyoon Song, Minna Lee, William Luo, Xiancheng Wu, Debra Chung, Richard J. Pietras, Helena R. Chang
Article
Biochemistry & Molecular Biology
Patricia A. Young, Reiko E. Yamada, Kham R. Trinh, Alex Vasuthasawat, Satiro De Oliveira, Douglas H. Yamada, Sherie L. Morrison, John M. Timmerman
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
(2018)
Review
Cell Biology
Viroj Boonyaratanakornkit, Nalo Hamilton, Diana C. Marquez-Garban, Prangwan Pateetin, Eileen M. McGowan, Richard J. Pietras
MOLECULAR AND CELLULAR ENDOCRINOLOGY
(2018)
Biographical-Item
Biochemistry & Molecular Biology
Richard J. Pietras
Review
Oncology
Mirela Tuzovic, Monica Mead, Patricia A. Young, Gary Schiller, Eric H. Yang
CURRENT ONCOLOGY REPORTS
(2019)
Article
Oncology
Diana C. Marquez-Garbana, Manuel Gorrin-Rivas, Hsiao-Wang Chen, Colin Sterling, David Elashoff, Nalo Hamilton, Richard J. Pietras
Article
Biochemistry & Molecular Biology
Diana C. Marquez-Garban, Gang Deng, Begonya Comin-Anduix, Alejandro J. Garcia, Yanpeng Xing, Hsiao-Wang Chen, Gardenia Cheung-Lau, Nalo Hamilton, Michael E. Jung, Richard J. Pietras
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2019)
Article
Oncology
Patricia A. Young, Daria Gaut, Davis K. Kimaiyo, Jonathan Grotts, Tahmineh Romero, John Chute, Gary Schiller, Sven de Vos, Herbert A. Eradat, John Timmerman
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2020)
Review
Pathology
Mark G. Evans, Roberto N. Miranda, Patricia A. Young, Linda Pai, Huan-You Wang, Sergej N. Konoplev, L. Jeffrey Medeiros, Lauren C. Pinter-Brown
ANNALS OF DIAGNOSTIC PATHOLOGY
(2020)
Article
Oncology
Daria Gaut, Kevin Tang, Myung Shin Sim, Tuyen Duong, Patricia Young, Joshua Sasine
Summary: A retrospective analysis was done on 22 relapsed/refractory DLBCL patients who received CAR T-cell therapy, with 31.8% of them receiving Filgrastim which led to a significantly shorter duration of neutropenia. However, the rate of infection did not differ based on Filgrastim use.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Hematology
Sandy On, Carolyn G. Rath, Michelle Lan, Bobby Wu, Kimberly M. Lau, Edna Cheung, William Alegria, Rebecca Young, Marisela Tan, Carrie Kim, Jennifer Phun, Nimish Patel, Gabriel Mannis, Aaron C. Logan, Vanessa Kennedy, Aaron Goodman, Randy A. Taplitz, Patricia A. Young, Raymond Wen, Ila M. Saunders
Summary: This study investigated the incidence of invasive fungal infections and other infectious complications in patients with acute myeloid leukaemia receiving venetoclax and hypomethylating agent therapy. The results showed a low incidence of IFIs, but an increase in bacterial infections and hospital admissions due to neutropenic fever.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Letter
Hematology
Nadeem Tabbara, Jack Sharp, Daria Gaut, Thanh Thuy Dan Pham, Kevin Tang, Caspian Oliai, Myung Shin Sim, Gary Schiller, Patricia Young, Joshua P. Sasine
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Oncology
Tamer Othman, Michelle A. Quan, Shiliang Zhang, Daria Gaut, Patricia A. Young, Omar Mahmood, Haifaa Abdulhaq, Kevin Shieh, Jack Reid, Elizabeth A. Brem, Nisha Hariharan, Benjamin Heyman, Joseph Tuscano
Summary: This study retrospectively analyzed PCNSL patients who received autologous hematopoietic cell transplantation or nonmyeloablative chemotherapy in CR1. The results showed that autologous hematopoietic cell transplantation in CR1 can improve outcomes in eligible patients.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)